1 / 20

Outline

Data on the world drug situation: Gaps and opportunities Sandeep Chawla Director Division for Policy Analysis and Public Affairs, UNODC. Outline. Why collect and analyse data on the drug situation? Existing data and indicators of the world drug situation Production Seizures Prices Use

dacian
Download Presentation

Outline

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Data on the world drug situation: Gaps and opportunities Sandeep ChawlaDirectorDivision for Policy Analysis and Public Affairs, UNODC

  2. Outline Why collect and analyse data on the drug situation? Existing data and indicators of the world drug situation Production Seizures Prices Use Data availability present gaps opportunities moving forwards

  3. Drug production

  4. Opium and cocaine production:Methods developed, reasonable certainty Opium Cocaine

  5. Wide range of potential cultivation areas Wide variety of cultivation practices Many different cultivation scales and intensities Different processing and products Global cannabis production: estimation remains a challenge Outdoor areas potentially suitable for cannabis cultivation

  6. Global ATS production, 1998-2007: Great uncertainty, and need for critique and improvement

  7. Drug seizures

  8. Drug seizure data – average improvements in recording HOWEVER Africa and Oceania still lack capacity, and data quality remains an issue

  9. Drug prices

  10. UNODC prices data collection: opium and coca products Monthly farm-gate prices coca leaf and derivatives (Bolivia, Colombia, Peru) opium (Afghanistan, Myanmar) Monthly trader prices in production areas Export value estimation opium (Afghanistan) Consumer prices and purities collected through ARQ

  11. Price data collection challenges Very limited and outdated data: Wholesale level (country to country) Street level prices (except in some high income countries) Purity Poorly monitored and reported Value added along trafficking routes Poorly understood

  12. Drug use

  13. Data incredibly limited: drug use prevalence estimates

  14. Drug use data Very few objective data on drug use Even fewer direct measures of trends in drug use Expert perceptions of trends most common source, but unknown validity Improve reporting against the 2000 Lisbon consensus? Drug use: general population, young people “High risk” drug use: injecting, risk behaviours Drug problems

  15. Moving forward:Increasing data collection and consolidation

  16. Data collection Build data collection capacity Develop drug information systems in regions of need Support studies of drug use prevalence Encourage collaborative links between countries within regions Use a strategic focus to direct activities Build the SMART programme Development of a new programme to improve drug use data collection Maximise integration with other data collection Other health surveys and studies Other regional drug information systems

  17. Methodological issues The ARQ and BRQ Are they still fit for purpose? Can we improve reporting processes and outcomes? Data are often unclear or inconsistent How should UNODC deal with such data? Are additional review processes warranted? How can regional and global estimates best be made? Methods of data imputation Logic behind extrapolation of estimates to other countries

  18. Addressing uncertainty Explicitly acknowledge and estimate uncertainty Increased transparency, critique and consultation Shared approach to data collection and interpretation Better coordination and collaboration With member states With drug monitoring organisations With other external partners and experts

  19. Revising global data collection: March 2009 mandate • CND meeting in Vienna • Debates about current data • Debates about future processes • Political declaration re-stated the importance of data to inform evidence-based drug policy • Resolution passed that tasked UNODC with: • revising the Annual Reports Questionnaire • Improving and streamlining integrated data collection at the global level

  20. Revising global data collection: the coming year Review process being undertaken by UNODC: • UNODC Expert meeting in July 2009: Vienna, Austria • Recommendations made for revisions to both process and tools – for consideration in November • Intergovernmental Expert Group meeting in November 2009: Vienna, Austria • Revised ARQ process and questionnaire developed for consideration by CND • UNODC reporting back to CND in March 2010: consideration and ratification

More Related